Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional insulin regimen in type 2 diabetes mellitus patients with poor glycemic control pretreated with a two-injection conventional insulin therapy.

Next Previous
X
Search
Trial Profile

52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional insulin regimen in type 2 diabetes mellitus patients with poor glycemic control pretreated with a two-injection conventional insulin therapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary) ; Insulin aspart; Insulins
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GINGER
  • Sponsors Sanofi

    • Most Recent Events

    • 20 Sep 2010 Tolerability results presented at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD 2010).
    • 01 Feb 2010 Results published in Diabetes, Obesity and Metabolism.
    • 07 Jul 2009 Actual patient number changed from 310 to 311 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top